Phage Therapy BX002 Shows Promise in First-in-human Trial

Phage Therapy BX002 Shows Promise in First-in-human Trial

285748

Phage Therapy BX002 Shows Promise in First-in-human Trial

BX002, an oral phage therapy BiomX is developing for inflammatory bowel disease (IBD), showed a good safety profile, as well as the ability to effectively deliver its active agent to the gut, in a first-in-human clinical trial, the company announced in a press release. The human gut is home to billions of bacteria — the gut microbiome — and these tiny organisms play an important part in human health. Abnormalities in the gut microbiome have…

You must be logged in to read/download the full post.